Survival after Definitive (Chemo)Radiotherapy in Esophageal Cancer Patients: A Population-Based Study in the North-East Netherlands
Background Definitive (chemo)radiotherapy is employed in esophageal cancer patients as an alternative for patients considered medically unfit for surgery or having unresectable tumors. We evaluated a population-based cohort to improve the selection for intensified nonsurgical strategies and to ident...
Saved in:
Published in | Annals of surgical oncology Vol. 20; no. 6; pp. 1985 - 1992 |
---|---|
Main Authors | , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
New York
Springer-Verlag
01.06.2013
Springer Nature B.V |
Subjects | |
Online Access | Get full text |
ISSN | 1068-9265 1534-4681 1534-4681 |
DOI | 10.1245/s10434-012-2824-2 |
Cover
Abstract | Background
Definitive (chemo)radiotherapy is employed in esophageal cancer patients as an alternative for patients considered medically unfit for surgery or having unresectable tumors. We evaluated a population-based cohort to improve the selection for intensified nonsurgical strategies and to identify prognostic factors.
Methods
Patients who had squamous cell carcinoma (SCC) or adenocarcinoma (AC) were treated in four referral centers in the north-east Netherlands with definitive chemoradiotherapy (dCRT) or radiotherapy (dRT) between 1996 and 2008.
Results
Of the 287 included patients, 110 were treated with dCRT and 177 with dRT. Median overall survival (OS) was 11 months (95 % confidence interval: 10–12 months), with OS of 22 and 8 % and disease-free survival (DFS) of 16 and 5 % at 2 and 5 years, respectively. DFS at 2 and 5 years was 24 and 9 % for SCC versus 10 and 2 % for AC patients (
P
= 0.006). OS after 2 and 5 years was 29 and 14 % for SCC patients versus 17 and 3 % for AC patients (
P
= 0.044). On multivariate Cox regression, SCC was an independent prognostic factor for DFS [
P
= 0.020, hazard ratio (HR) = 0.71] and OS (
P
= 0.047, HR = 0.76). On matched cohort analysis, DFS was higher in the dCRT group compared with dRT patients (
P
= 0.016). The locoregional failure rate was lower in the dCRT group and in SCC patients (
P
= 0.001 and 0.046).
Conclusions
Long-term results and the local control rate in SCC patients were better after definitive (chemo)radiotherapy compared with in AC patients. SCC was an independent prognostic factor for survival. Definitive chemoradiotherapy leads to improved local control rate and DFS. |
---|---|
AbstractList | Definitive (chemo)radiotherapy is employed in esophageal cancer patients as an alternative for patients considered medically unfit for surgery or having unresectable tumors. We evaluated a population-based cohort to improve the selection for intensified nonsurgical strategies and to identify prognostic factors.
Patients who had squamous cell carcinoma (SCC) or adenocarcinoma (AC) were treated in four referral centers in the north-east Netherlands with definitive chemoradiotherapy (dCRT) or radiotherapy (dRT) between 1996 and 2008.
Of the 287 included patients, 110 were treated with dCRT and 177 with dRT. Median overall survival (OS) was 11 months (95 % confidence interval: 10-12 months), with OS of 22 and 8 % and disease-free survival (DFS) of 16 and 5 % at 2 and 5 years, respectively. DFS at 2 and 5 years was 24 and 9 % for SCC versus 10 and 2 % for AC patients (P = 0.006). OS after 2 and 5 years was 29 and 14 % for SCC patients versus 17 and 3 % for AC patients (P = 0.044). On multivariate Cox regression, SCC was an independent prognostic factor for DFS [P = 0.020, hazard ratio (HR) = 0.71] and OS (P = 0.047, HR = 0.76). On matched cohort analysis, DFS was higher in the dCRT group compared with dRT patients (P = 0.016). The locoregional failure rate was lower in the dCRT group and in SCC patients (P = 0.001 and 0.046).
Long-term results and the local control rate in SCC patients were better after definitive (chemo)radiotherapy compared with in AC patients. SCC was an independent prognostic factor for survival. Definitive chemoradiotherapy leads to improved local control rate and DFS. Background Definitive (chemo)radiotherapy is employed in esophageal cancer patients as an alternative for patients considered medically unfit for surgery or having unresectable tumors. We evaluated a population-based cohort to improve the selection for intensified nonsurgical strategies and to identify prognostic factors. Methods Patients who had squamous cell carcinoma (SCC) or adenocarcinoma (AC) were treated in four referral centers in the north-east Netherlands with definitive chemoradiotherapy (dCRT) or radiotherapy (dRT) between 1996 and 2008. Results Of the 287 included patients, 110 were treated with dCRT and 177 with dRT. Median overall survival (OS) was 11 months (95 % confidence interval: 10–12 months), with OS of 22 and 8 % and disease-free survival (DFS) of 16 and 5 % at 2 and 5 years, respectively. DFS at 2 and 5 years was 24 and 9 % for SCC versus 10 and 2 % for AC patients ( P = 0.006). OS after 2 and 5 years was 29 and 14 % for SCC patients versus 17 and 3 % for AC patients ( P = 0.044). On multivariate Cox regression, SCC was an independent prognostic factor for DFS [ P = 0.020, hazard ratio (HR) = 0.71] and OS ( P = 0.047, HR = 0.76). On matched cohort analysis, DFS was higher in the dCRT group compared with dRT patients ( P = 0.016). The locoregional failure rate was lower in the dCRT group and in SCC patients ( P = 0.001 and 0.046). Conclusions Long-term results and the local control rate in SCC patients were better after definitive (chemo)radiotherapy compared with in AC patients. SCC was an independent prognostic factor for survival. Definitive chemoradiotherapy leads to improved local control rate and DFS. Definitive (chemo)radiotherapy is employed in esophageal cancer patients as an alternative for patients considered medically unfit for surgery or having unresectable tumors. We evaluated a population-based cohort to improve the selection for intensified nonsurgical strategies and to identify prognostic factors.BACKGROUNDDefinitive (chemo)radiotherapy is employed in esophageal cancer patients as an alternative for patients considered medically unfit for surgery or having unresectable tumors. We evaluated a population-based cohort to improve the selection for intensified nonsurgical strategies and to identify prognostic factors.Patients who had squamous cell carcinoma (SCC) or adenocarcinoma (AC) were treated in four referral centers in the north-east Netherlands with definitive chemoradiotherapy (dCRT) or radiotherapy (dRT) between 1996 and 2008.METHODSPatients who had squamous cell carcinoma (SCC) or adenocarcinoma (AC) were treated in four referral centers in the north-east Netherlands with definitive chemoradiotherapy (dCRT) or radiotherapy (dRT) between 1996 and 2008.Of the 287 included patients, 110 were treated with dCRT and 177 with dRT. Median overall survival (OS) was 11 months (95 % confidence interval: 10-12 months), with OS of 22 and 8 % and disease-free survival (DFS) of 16 and 5 % at 2 and 5 years, respectively. DFS at 2 and 5 years was 24 and 9 % for SCC versus 10 and 2 % for AC patients (P = 0.006). OS after 2 and 5 years was 29 and 14 % for SCC patients versus 17 and 3 % for AC patients (P = 0.044). On multivariate Cox regression, SCC was an independent prognostic factor for DFS [P = 0.020, hazard ratio (HR) = 0.71] and OS (P = 0.047, HR = 0.76). On matched cohort analysis, DFS was higher in the dCRT group compared with dRT patients (P = 0.016). The locoregional failure rate was lower in the dCRT group and in SCC patients (P = 0.001 and 0.046).RESULTSOf the 287 included patients, 110 were treated with dCRT and 177 with dRT. Median overall survival (OS) was 11 months (95 % confidence interval: 10-12 months), with OS of 22 and 8 % and disease-free survival (DFS) of 16 and 5 % at 2 and 5 years, respectively. DFS at 2 and 5 years was 24 and 9 % for SCC versus 10 and 2 % for AC patients (P = 0.006). OS after 2 and 5 years was 29 and 14 % for SCC patients versus 17 and 3 % for AC patients (P = 0.044). On multivariate Cox regression, SCC was an independent prognostic factor for DFS [P = 0.020, hazard ratio (HR) = 0.71] and OS (P = 0.047, HR = 0.76). On matched cohort analysis, DFS was higher in the dCRT group compared with dRT patients (P = 0.016). The locoregional failure rate was lower in the dCRT group and in SCC patients (P = 0.001 and 0.046).Long-term results and the local control rate in SCC patients were better after definitive (chemo)radiotherapy compared with in AC patients. SCC was an independent prognostic factor for survival. Definitive chemoradiotherapy leads to improved local control rate and DFS.CONCLUSIONSLong-term results and the local control rate in SCC patients were better after definitive (chemo)radiotherapy compared with in AC patients. SCC was an independent prognostic factor for survival. Definitive chemoradiotherapy leads to improved local control rate and DFS. Definitive (chemo)radiotherapy is employed in esophageal cancer patients as an alternative for patients considered medically unfit for surgery or having unresectable tumors. We evaluated a population-based cohort to improve the selection for intensified nonsurgical strategies and to identify prognostic factors. Patients who had squamous cell carcinoma (SCC) or adenocarcinoma (AC) were treated in four referral centers in the north-east Netherlands with definitive chemoradiotherapy (dCRT) or radiotherapy (dRT) between 1996 and 2008. Of the 287 included patients, 110 were treated with dCRT and 177 with dRT. Median overall survival (OS) was 11 months (95 % confidence interval: 10-12 months), with OS of 22 and 8 % and disease-free survival (DFS) of 16 and 5 % at 2 and 5 years, respectively. DFS at 2 and 5 years was 24 and 9 % for SCC versus 10 and 2 % for AC patients (P = 0.006). OS after 2 and 5 years was 29 and 14 % for SCC patients versus 17 and 3 % for AC patients (P = 0.044). On multivariate Cox regression, SCC was an independent prognostic factor for DFS [P = 0.020, hazard ratio (HR) = 0.71] and OS (P = 0.047, HR = 0.76). On matched cohort analysis, DFS was higher in the dCRT group compared with dRT patients (P = 0.016). The locoregional failure rate was lower in the dCRT group and in SCC patients (P = 0.001 and 0.046). Long-term results and the local control rate in SCC patients were better after definitive (chemo)radiotherapy compared with in AC patients. SCC was an independent prognostic factor for survival. Definitive chemoradiotherapy leads to improved local control rate and DFS.[PUBLICATION ABSTRACT] |
Author | Mul, Véronique E. Langendijk, Johannes A. Muijs, Christina T. Timmer, Paul R. Beukema, Jannet C. Muller, Karin Hospers, Geke A. P. Smit, Justin K. Plukker, John Th. M. Burgerhof, Johannes G. M. Woutersen, Dankert Paardekooper, Gabriel van Dijk, Boukje A. C. |
Author_xml | – sequence: 1 givenname: Justin K. surname: Smit fullname: Smit, Justin K. organization: Surgical Oncology of the University Medical Center Groningen, University of Groningen – sequence: 2 givenname: Christina T. surname: Muijs fullname: Muijs, Christina T. organization: Radiation Oncology of the University Medical Center Groningen, University of Groningen – sequence: 3 givenname: Johannes G. M. surname: Burgerhof fullname: Burgerhof, Johannes G. M. organization: Epidemiology of the University Medical Center Groningen, University of Groningen – sequence: 4 givenname: Gabriel surname: Paardekooper fullname: Paardekooper, Gabriel organization: Radiation Oncology, Isala Klinieken – sequence: 5 givenname: Paul R. surname: Timmer fullname: Timmer, Paul R. organization: Radiation Oncology, Isala Klinieken – sequence: 6 givenname: Karin surname: Muller fullname: Muller, Karin organization: Radiotherapy Institute Stedendriehoek en Omstreken – sequence: 7 givenname: Dankert surname: Woutersen fullname: Woutersen, Dankert organization: Medisch Spectrum Twente – sequence: 8 givenname: Véronique E. surname: Mul fullname: Mul, Véronique E. organization: Radiation Oncology of the University Medical Center Groningen, University of Groningen – sequence: 9 givenname: Jannet C. surname: Beukema fullname: Beukema, Jannet C. organization: Radiation Oncology of the University Medical Center Groningen, University of Groningen – sequence: 10 givenname: Geke A. P. surname: Hospers fullname: Hospers, Geke A. P. organization: Medical Oncology of the University Medical Center Groningen, University of Groningen – sequence: 11 givenname: Boukje A. C. surname: van Dijk fullname: van Dijk, Boukje A. C. organization: Section of Epidemiology, Comprehensive Cancer Centers – sequence: 12 givenname: Johannes A. surname: Langendijk fullname: Langendijk, Johannes A. organization: Radiation Oncology of the University Medical Center Groningen, University of Groningen – sequence: 13 givenname: John Th. M. surname: Plukker fullname: Plukker, John Th. M. email: j.t.m.plukker@umcg.nl organization: Surgical Oncology of the University Medical Center Groningen, University of Groningen |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/23274534$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kUtvEzEURi1URNvAD2CDLLEpC4Nf45mwKyE8pKpUFNaW47luXE3swfZE6po_jpO0EqoEKz90zqer756ioxADIPSS0beMy-ZdZlQKSSjjhHdcEv4EnbCm_kjVsaN6p6ojc66aY3Sa8y2lrBW0eYaOueCtrOAJ-n09pa3fmgEbVyDhj-B88MVvAZ8t1rCJb76b3seyhmTGO-wDXuY4rs0NVGVhgq3OlSkeQsnv8Tm-iuM01HcM5IPJ0OPrMvV7r0bgy5jKmixNLvgSdpmDCX1-jp46M2R4cX_O0M9Pyx-LL-Ti2-evi_MLYqXoClFqTudOKbGyXSuhMbI1jbNMrHrlHHDhTMNcR8FSqmxvlBWKq3lFOpAgpJihs0PumOKvCXLRG58tDHUIiFPWTDSiFlrtir5-hN7GKYU63Z5qa7_7wFf31LTaQK_H5Dcm3emHeivQHgCbYs4JnLa-7NspyfhBM6p3i9SHReq6SL1bZA2YIfbIfAj_n8MPTq5suIH019D_lP4ACp-vZw |
CitedBy_id | crossref_primary_10_1186_1748_717X_9_191 crossref_primary_10_1158_1078_0432_CCR_18_0205 crossref_primary_10_1093_annonc_mdt589 crossref_primary_10_1016_j_canrad_2019_06_014 crossref_primary_10_1016_j_ijrobp_2017_02_097 crossref_primary_10_1080_0284186X_2018_1450521 crossref_primary_10_1016_j_arcmed_2020_04_013 crossref_primary_10_1080_0284186X_2022_2036366 crossref_primary_10_1245_s10434_024_16490_4 crossref_primary_10_1186_s13014_018_1044_8 crossref_primary_10_1016_j_bpg_2018_11_011 crossref_primary_10_1002_jcb_25829 crossref_primary_10_1186_s13014_021_01931_1 |
Cites_doi | 10.1200/JCO.2005.00.034 10.1016/j.ijrobp.2008.08.046 10.1056/NEJM199206113262403 10.1245/ASO.2003.03.078 10.1016/S1470-2045(11)70142-5 10.1200/JCO.2008.20.9288 10.1136/gut.2003.025080 10.1016/S1470-2045(07)70172-9 10.1200/JCO.20.5.1167 10.1016/j.ejca.2007.03.024 10.1016/S1470-2045(07)70039-6 10.1093/jnci/djn211 10.1016/j.jtcvs.2011.01.053 10.1002/(SICI)1097-0142(20000301)88:5<988::AID-CNCR7>3.0.CO;2-U 10.1097/JTO.0b013e31802bff75 10.1016/j.radonc.2006.01.009 10.1200/JCO.2010.33.0597 10.1016/S0360-3016(98)00232-6 10.1200/JCO.2005.04.7118 10.1002/pds.969 10.1016/S1470-2045(05)70288-6 10.1097/SLA.0b013e31815c4037 10.1002/ssu.10017 10.1016/S0167-8140(98)00037-1 10.1056/NEJMoa055531 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B 10.1016/j.amjsurg.2009.12.006 10.1016/j.radonc.2011.07.021 |
ContentType | Journal Article |
Copyright | Society of Surgical Oncology 2012 Society of Surgical Oncology 2013 |
Copyright_xml | – notice: Society of Surgical Oncology 2012 – notice: Society of Surgical Oncology 2013 |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7TO 7X7 7XB 88E 8AO 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH H94 K9. M0S M1P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 |
DOI | 10.1245/s10434-012-2824-2 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic Oncogenes and Growth Factors Abstracts |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1534-4681 |
EndPage | 1992 |
ExternalDocumentID | 2977024471 23274534 10_1245_s10434_012_2824_2 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GeographicLocations | Netherlands |
GeographicLocations_xml | – name: Netherlands |
GroupedDBID | --- -53 -5E -5G -BR -EM -Y2 -~C .86 .VR 06C 06D 0R~ 0VY 199 1N0 1SB 203 23M 28- 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2WC 2~H 30V 3V. 4.4 406 408 409 40D 40E 53G 5GY 5QI 5VS 67Z 6J9 6NX 78A 7X7 88E 8AO 8FI 8FJ 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAYIU AAYQN AAYTO AAYZH ABAKF ABBBX ABBXA ABDZT ABECU ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKCH ABKTR ABMNI ABMQK ABNWP ABOCM ABPLI ABQBU ABQSL ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABUWZ ABWNU ABXPI ACAOD ACBXY ACDTI ACGFO ACGFS ACHSB ACHVE ACHXU ACIHN ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACPRK ACREN ACUDM ACZOJ ADBBV ADHHG ADHIR ADIMF ADINQ ADJJI ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADYOE ADZKW AEAQA AEBTG AEFIE AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFEXP AFJLC AFKRA AFLOW AFQWF AFWTZ AFYQB AFZKB AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGRTI AGVAE AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMTXH AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BAWUL BBWZM BDATZ BENPR BGNMA BPHCQ BSONS BVXVI C1A CAG CCPQU COF CS3 CSCUP DDRTE DIK DL5 DNIVK DPUIP E3Z EBD EBLON EBS EIOEI EJD EMOBN EN4 ESBYG F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GRRUI GX1 GXS H13 HEOXT HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IH2 IHE IJ- IKXTQ IMOTQ IWAJR IXC IXD IXE IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KOW KPH L7B LAS LLZTM M1P M4Y MA- N2Q N9A NB0 NDZJH NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM OVD OWW P19 P2P P9S PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R4E R89 R9I RHV RNI ROL RPX RRX RSV RZK S16 S1Z S26 S27 S28 S37 S3B SAP SCLPG SDE SDH SDM SHX SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 T16 TEORI TSG TSK TSV TT1 TUC U2A U9L UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK8 WOQ YFH YLTOR Z45 Z7U Z7X Z82 Z83 Z87 Z8O Z8V Z91 ZMTXR ZOVNA AAPKM AAYXX ABBRH ABDBE ABFSG ACMFV ACSTC ADHKG AEZWR AFDZB AFHIU AFOHR AGQPQ AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT CGR CUY CVF ECM EIF NPM 7TO 7XB 8FK ABRTQ H94 K9. PJZUB PKEHL PPXIY PQEST PQUKI PRINS PUEGO 7X8 |
ID | FETCH-LOGICAL-c438t-66909f663bc874e5a47a5fc13bd6ffe23fa51f80ec006cda6c362695fc8e4e343 |
IEDL.DBID | AGYKE |
ISSN | 1068-9265 1534-4681 |
IngestDate | Thu Sep 04 22:16:24 EDT 2025 Sat Aug 23 14:10:10 EDT 2025 Thu Apr 03 07:09:54 EDT 2025 Tue Jul 01 02:08:29 EDT 2025 Thu Apr 24 23:00:34 EDT 2025 Fri Feb 21 02:33:17 EST 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 6 |
Keywords | Squamous Cell Carcinoma Radiation Therapy Oncology Group Gross Tumor Volume Overall Survival Squamous Cell Carcinoma Patient |
Language | English |
License | http://www.springer.com/tdm |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c438t-66909f663bc874e5a47a5fc13bd6ffe23fa51f80ec006cda6c362695fc8e4e343 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 |
PMID | 23274534 |
PQID | 1353768134 |
PQPubID | 32486 |
PageCount | 8 |
ParticipantIDs | proquest_miscellaneous_1353043006 proquest_journals_1353768134 pubmed_primary_23274534 crossref_citationtrail_10_1245_s10434_012_2824_2 crossref_primary_10_1245_s10434_012_2824_2 springer_journals_10_1245_s10434_012_2824_2 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2013-06-01 |
PublicationDateYYYYMMDD | 2013-06-01 |
PublicationDate_xml | – month: 06 year: 2013 text: 2013-06-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | New York |
PublicationPlace_xml | – name: New York – name: United States |
PublicationTitle | Annals of surgical oncology |
PublicationTitleAbbrev | Ann Surg Oncol |
PublicationTitleAlternate | Ann Surg Oncol |
PublicationYear | 2013 |
Publisher | Springer-Verlag Springer Nature B.V |
Publisher_xml | – name: Springer-Verlag – name: Springer Nature B.V |
References | Cooper, Guo, Herskovic, Macdonald, Martenson, Al-Sarraf (CR11) 1999; 281 Herskovic, Martz, al-Sarraf, Leichman, Brindle, Vaitkevicius (CR12) 1992; 326 Fiorica, Di Bona, Schepis, Licata, Di Shahied, Venturi (CR26) 2004; 53 Sobin (CR19) 2003; 21 Kaklamanos, Walker, Ferry, Franceschi, Livingstone (CR9) 2003; 10 Bedenne, Michel, Bouche, Milan, Mariette, Conroy (CR17) 2007; 25 Mariette, Piessen, Triboulet (CR5) 2007; 8 Smit, Pultrum, Dullemen, Dam, Groen, Plukker (CR7) 2010; 200 Ychou, Boige, Pignon, Conroy, Bouché, Lebreton (CR29) 2011; 29 Gaast, van Hagen, Hulshof, Richel, van Berge Henegouwen, Nieuwenhuijzen (CR25) 2010; 28 Gaspar, Winter, Kocha, Coia, Herskovic, Graham (CR18) 2000; 88 CR3 Muijs, Beukema, Mul, Plukker, Sijtsema, Langendijk (CR13) 2011; 102 Smith, Ryan, Douglass, Haller, Dayal, Kirkwood (CR14) 1998; 42 Stahl, Stuschke, Lehmann, Meyer, Walz, Seeber (CR16) 2005; 23 Wang, Ryu, Gandara, Bold, Urayama, Tanaka (CR20) 2007; 2 Geh, Bond, Bentzen, Glynne-Jones (CR15) 2006; 78 Burmeister, Smithers, Gebski, Fitzgerald, Simes, Devitt (CR24) 2005; 6 Omloo, Lagarde, Hulscher, Reitsma, Fockens, van Dekken (CR6) 2007; 246 Lee, Mirza, Port, Stiles, Paul, Christos, Altorki (CR27) 2011; 141 Minsky, Pajak, Ginsberg, Pisansky, Martenson, Komaki (CR30) 2002; 20 Cunningham, Allum, Stenning, Thompson, Van de Velde, Nicolson (CR28) 2006; 355 Crane, Schaapveld, Visser, Louwman, Plukker, van Dam (CR2) 2007; 43 Gebski, Burmeister, Smithers, Foo, Zalcberg, Simes (CR8) 2007; 8 Weitzen, Lapane, Toledano, Hume, Mor (CR22) 2004; 13 D’Agostino (CR21) 1998; 17 Brown, Devesa, Chow (CR1) 2008; 100 Smith, Smith, Buchholz, Liao, Jeter, Swisher (CR4) 2009; 74 Sjoquist, Burmeister, Smithers, Zalcberg, Simes, Barbour (CR10) 2011; 12 Sykes, Burt, Slevin, Stout, Marrs (CR23) 1998; 48 JS Cooper (2824_CR11) 1999; 281 2824_CR7 TJ Smith (2824_CR14) 1998; 42 F Fiorica (2824_CR26) 2004; 53 M Ychou (2824_CR29) 2011; 29 LH Sobin (2824_CR19) 2003; 21 2824_CR13 H Wang (2824_CR20) 2007; 2 C Mariette (2824_CR5) 2007; 8 RB D’Agostino Jr (2824_CR21) 1998; 17 M Stahl (2824_CR16) 2005; 23 JI Geh (2824_CR15) 2006; 78 BH Burmeister (2824_CR24) 2005; 6 S Weitzen (2824_CR22) 2004; 13 BD Minsky (2824_CR30) 2002; 20 LM Crane (2824_CR2) 2007; 43 D Cunningham (2824_CR28) 2006; 355 KM Sjoquist (2824_CR10) 2011; 12 2824_CR3 LM Brown (2824_CR1) 2008; 100 V Gebski (2824_CR8) 2007; 8 GL Omloo (2824_CR6) 2007; 246 GL Smith (2824_CR4) 2009; 74 AJ Sykes (2824_CR23) 1998; 48 PC Lee (2824_CR27) 2011; 141 AV Gaast (2824_CR25) 2010; 28 LE Gaspar (2824_CR18) 2000; 88 A Herskovic (2824_CR12) 1992; 326 L Bedenne (2824_CR17) 2007; 25 IG Kaklamanos (2824_CR9) 2003; 10 |
References_xml | – volume: 23 start-page: 2310 year: 2005 end-page: 2317 ident: CR16 article-title: Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus publication-title: J Clin Oncol doi: 10.1200/JCO.2005.00.034 – volume: 74 start-page: 482 year: 2009 end-page: 489 ident: CR4 article-title: Patterns of care and locoregional treatment outcomes in older esophageal cancer patients: the SEER-Medicare Cohort publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2008.08.046 – volume: 326 start-page: 1593 year: 1992 end-page: 1598 ident: CR12 article-title: Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus publication-title: N Engl J Med doi: 10.1056/NEJM199206113262403 – volume: 10 start-page: 754 year: 2003 end-page: 761 ident: CR9 article-title: Neoadjuvant treatment for resectable cancer of the esophagus and the gastroesophageal junction: a meta-analysis of randomized clinical trials publication-title: Ann Surg Oncol doi: 10.1245/ASO.2003.03.078 – volume: 12 start-page: 681 year: 2011 end-page: 692 ident: CR10 article-title: Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis publication-title: Lancet Oncol doi: 10.1016/S1470-2045(11)70142-5 – volume: 28 start-page: 15 year: 2010 ident: CR25 article-title: Effect of preoperative concurrent chemoradiotherapy on survival of patients with resectable esophageal or esophagogastric junction cancer: results from a multicenter randomized phase III study publication-title: J Clin Oncol doi: 10.1200/JCO.2008.20.9288 – volume: 53 start-page: 925 year: 2004 end-page: 930 ident: CR26 article-title: Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis publication-title: Gut doi: 10.1136/gut.2003.025080 – volume: 8 start-page: 545 year: 2007 end-page: 553 ident: CR5 article-title: Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities publication-title: Lancet Oncol doi: 10.1016/S1470-2045(07)70172-9 – volume: 20 start-page: 1167 year: 2002 end-page: 1174 ident: CR30 article-title: INT 0123 (Radiation Therapy Oncology Group 94–05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy publication-title: J Clin Oncol doi: 10.1200/JCO.20.5.1167 – volume: 43 start-page: 1445 year: 2007 end-page: 1451 ident: CR2 article-title: Oesophageal cancer in The Netherlands: increasing incidence and mortality but improving survival publication-title: Eur J Cancer doi: 10.1016/j.ejca.2007.03.024 – volume: 8 start-page: 226 year: 2007 end-page: 234 ident: CR8 article-title: Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis publication-title: Lancet Oncol doi: 10.1016/S1470-2045(07)70039-6 – volume: 100 start-page: 1184 year: 2008 end-page: 1187 ident: CR1 article-title: Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djn211 – volume: 141 start-page: 1196 year: 2011 end-page: 1206 ident: CR27 article-title: Predictors of recurrence and disease-free survival in patients with completely resected esophageal carcinoma publication-title: J Thorac Cardiovasc Surg doi: 10.1016/j.jtcvs.2011.01.053 – volume: 88 start-page: 988 year: 2000 end-page: 995 ident: CR18 article-title: A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group study 9207): final report publication-title: Cancer doi: 10.1002/(SICI)1097-0142(20000301)88:5<988::AID-CNCR7>3.0.CO;2-U – volume: 200 start-page: 446 year: 2010 end-page: 53 ident: CR7 article-title: Prognostic factors and patterns of recurrence in esophageal cancer assert arguments for extended two-field transthoracic esophagectomy publication-title: Am J Surg. – volume: 2 start-page: 153 year: 2007 end-page: 157 ident: CR20 article-title: A phase II study of paclitaxel, carboplatin, and radiation with or without surgery for esophageal cancer publication-title: J Thorac Oncol doi: 10.1097/JTO.0b013e31802bff75 – volume: 78 start-page: 236 year: 2006 end-page: 244 ident: CR15 article-title: Systematic overview of preoperative (neoadjuvant) chemoradiotherapy trials in oesophageal cancer: evidence of a radiation and chemotherapy dose response publication-title: Radiother Oncol doi: 10.1016/j.radonc.2006.01.009 – volume: 29 start-page: 1715 year: 2011 end-page: 1721 ident: CR29 article-title: Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial publication-title: J Clin Oncol doi: 10.1200/JCO.2010.33.0597 – ident: CR3 – volume: 42 start-page: 269 year: 1998 end-page: 276 ident: CR14 article-title: Combined chemoradiotherapy vs. radiotherapy alone for early stage squamous cell carcinoma of the esophagus: a study of the Eastern Cooperative Oncology Group publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/S0360-3016(98)00232-6 – volume: 25 start-page: 1160 year: 2007 end-page: 1168 ident: CR17 article-title: Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102 publication-title: J Clin Oncol doi: 10.1200/JCO.2005.04.7118 – volume: 13 start-page: 841 year: 2004 end-page: 853 ident: CR22 article-title: Principles for modeling propensity scores in medical research: a systematic literature review publication-title: Pharmacoepidemiol Drug Saf doi: 10.1002/pds.969 – volume: 6 start-page: 659 year: 2005 end-page: 668 ident: CR24 article-title: Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(05)70288-6 – volume: 246 start-page: 992 year: 2007 end-page: 1001 ident: CR6 article-title: Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial publication-title: Ann Surg doi: 10.1097/SLA.0b013e31815c4037 – volume: 21 start-page: 19 year: 2003 end-page: 22 ident: CR19 article-title: TNM, sixth edition: new developments in general concepts and rules publication-title: Semin Surg Oncol doi: 10.1002/ssu.10017 – volume: 48 start-page: 15 year: 1998 end-page: 21 ident: CR23 article-title: Radical radiotherapy for carcinoma of the oesophagus: an effective alternative to surgery publication-title: Radiother Oncol doi: 10.1016/S0167-8140(98)00037-1 – volume: 355 start-page: 11 year: 2006 end-page: 20 ident: CR28 article-title: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa055531 – volume: 281 start-page: 1623 year: 1999 end-page: 1627 ident: CR11 article-title: Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85–01) publication-title: Radiation Therapy Oncology Group. JAMA – volume: 102 start-page: 303 issue: 2 year: 2011 end-page: 8 ident: CR13 article-title: External beam radiotherapy combined with intraluminal brachytherapy in esophageal carcinoma publication-title: Radiother Oncol – volume: 17 start-page: 2265 year: 1998 end-page: 2281 ident: CR21 article-title: Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group publication-title: Stat Med doi: 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B – volume: 28 start-page: 15 year: 2010 ident: 2824_CR25 publication-title: J Clin Oncol doi: 10.1200/JCO.2008.20.9288 – volume: 12 start-page: 681 year: 2011 ident: 2824_CR10 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(11)70142-5 – volume: 17 start-page: 2265 year: 1998 ident: 2824_CR21 publication-title: Stat Med doi: 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B – volume: 2 start-page: 153 year: 2007 ident: 2824_CR20 publication-title: J Thorac Oncol doi: 10.1097/JTO.0b013e31802bff75 – volume: 88 start-page: 988 year: 2000 ident: 2824_CR18 publication-title: Cancer doi: 10.1002/(SICI)1097-0142(20000301)88:5<988::AID-CNCR7>3.0.CO;2-U – volume: 13 start-page: 841 year: 2004 ident: 2824_CR22 publication-title: Pharmacoepidemiol Drug Saf doi: 10.1002/pds.969 – ident: 2824_CR7 doi: 10.1016/j.amjsurg.2009.12.006 – volume: 8 start-page: 226 year: 2007 ident: 2824_CR8 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(07)70039-6 – volume: 21 start-page: 19 year: 2003 ident: 2824_CR19 publication-title: Semin Surg Oncol doi: 10.1002/ssu.10017 – volume: 23 start-page: 2310 year: 2005 ident: 2824_CR16 publication-title: J Clin Oncol doi: 10.1200/JCO.2005.00.034 – volume: 141 start-page: 1196 year: 2011 ident: 2824_CR27 publication-title: J Thorac Cardiovasc Surg doi: 10.1016/j.jtcvs.2011.01.053 – volume: 246 start-page: 992 year: 2007 ident: 2824_CR6 publication-title: Ann Surg doi: 10.1097/SLA.0b013e31815c4037 – volume: 25 start-page: 1160 year: 2007 ident: 2824_CR17 publication-title: J Clin Oncol doi: 10.1200/JCO.2005.04.7118 – ident: 2824_CR13 doi: 10.1016/j.radonc.2011.07.021 – ident: 2824_CR3 – volume: 78 start-page: 236 year: 2006 ident: 2824_CR15 publication-title: Radiother Oncol doi: 10.1016/j.radonc.2006.01.009 – volume: 48 start-page: 15 year: 1998 ident: 2824_CR23 publication-title: Radiother Oncol doi: 10.1016/S0167-8140(98)00037-1 – volume: 74 start-page: 482 year: 2009 ident: 2824_CR4 publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2008.08.046 – volume: 53 start-page: 925 year: 2004 ident: 2824_CR26 publication-title: Gut doi: 10.1136/gut.2003.025080 – volume: 29 start-page: 1715 year: 2011 ident: 2824_CR29 publication-title: J Clin Oncol doi: 10.1200/JCO.2010.33.0597 – volume: 42 start-page: 269 year: 1998 ident: 2824_CR14 publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/S0360-3016(98)00232-6 – volume: 100 start-page: 1184 year: 2008 ident: 2824_CR1 publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djn211 – volume: 43 start-page: 1445 year: 2007 ident: 2824_CR2 publication-title: Eur J Cancer doi: 10.1016/j.ejca.2007.03.024 – volume: 8 start-page: 545 year: 2007 ident: 2824_CR5 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(07)70172-9 – volume: 355 start-page: 11 year: 2006 ident: 2824_CR28 publication-title: N Engl J Med doi: 10.1056/NEJMoa055531 – volume: 20 start-page: 1167 year: 2002 ident: 2824_CR30 publication-title: J Clin Oncol doi: 10.1200/JCO.20.5.1167 – volume: 281 start-page: 1623 year: 1999 ident: 2824_CR11 publication-title: Radiation Therapy Oncology Group. JAMA – volume: 10 start-page: 754 year: 2003 ident: 2824_CR9 publication-title: Ann Surg Oncol doi: 10.1245/ASO.2003.03.078 – volume: 326 start-page: 1593 year: 1992 ident: 2824_CR12 publication-title: N Engl J Med doi: 10.1056/NEJM199206113262403 – volume: 6 start-page: 659 year: 2005 ident: 2824_CR24 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(05)70288-6 |
SSID | ssj0017305 |
Score | 2.2079923 |
Snippet | Background
Definitive (chemo)radiotherapy is employed in esophageal cancer patients as an alternative for patients considered medically unfit for surgery or... Definitive (chemo)radiotherapy is employed in esophageal cancer patients as an alternative for patients considered medically unfit for surgery or having... |
SourceID | proquest pubmed crossref springer |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 1985 |
SubjectTerms | Adenocarcinoma - pathology Adenocarcinoma - radiotherapy Adenocarcinoma - therapy Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - therapeutic use Carboplatin - administration & dosage Carcinoma, Squamous Cell - pathology Carcinoma, Squamous Cell - radiotherapy Carcinoma, Squamous Cell - therapy Chemoradiotherapy Cisplatin - administration & dosage Confidence Intervals Disease-Free Survival Esophageal Neoplasms - pathology Esophageal Neoplasms - radiotherapy Esophageal Neoplasms - therapy Female Fluorouracil - administration & dosage Gastrointestinal Oncology Humans Kaplan-Meier Estimate Male Medicine Medicine & Public Health Middle Aged Neoplasm Recurrence, Local - pathology Netherlands Oncology Paclitaxel - administration & dosage Proportional Hazards Models Radiotherapy Dosage Surgery Surgical Oncology Survival Rate Tumor Burden |
SummonAdditionalLinks | – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1JS8QwFA4uIF7E3XEjggcXgm2apFMv4jIigiIuMLfSbDAgHXVmDp79477XZqoiem6Shn7vJe_1LR8hu4n1LtLg5CilJROp8izzvM3S2LkM_Akvq3Kxm1t19SSuu7IbfrgNQlrl-EysDmrbN_iP_Aj5GcA0jhNx8vLKkDUKo6uBQmOSTMdgiSB1Q9ptHK4YpFdW0U4FSs2VDFFNLiSWzokE8y-wOJkLxn_eS7-MzV-B0ur-uZwnc8FwpKc10gtkwpWLZOYmhMaXyMfDCLQe5IZWtN_0wvlenRhE97ArQH__vrC9UG_1Tnsl7SCDARwnMOUcsX-jd3WT1cExPaV3DbMXO4ObzlLMOKzmwRK0CvewTjEY0m8lw8vk6bLzeH7FAsMCMyJpDwGgDOAAo0ObdiqcLERaSG_iRFvlveOJL2Ts25EzoJzGFspg95oM876ccIlIVshU2S_dGqFG2ExnkbVg0wmlI20851a4zJo0KmLdItH4--YmtB9HFoznHN0QgCSvIckBkhwhyXmLHDRTXureG_8N3hyDlgc1HORfQtMiO81jUCCMihSl64_qMdj4LFItslqD3bwNzM1USJx9OEb_2-J_bWX9_61skFlec2qA-G2SqeHbyG2BZTPU25X4fgIFVPNG priority: 102 providerName: ProQuest |
Title | Survival after Definitive (Chemo)Radiotherapy in Esophageal Cancer Patients: A Population-Based Study in the North-East Netherlands |
URI | https://link.springer.com/article/10.1245/s10434-012-2824-2 https://www.ncbi.nlm.nih.gov/pubmed/23274534 https://www.proquest.com/docview/1353768134 https://www.proquest.com/docview/1353043006 |
Volume | 20 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlR3LbtQwcFRaCXEp73ahVEbqoYBSJY7tbLht25Q-1GpVutJyiuKXtAJlUTd7gCs_zjh2okIpUi-JlHgcZzwzntG8AHZSbU0s0cgRQvKIZcJGuaXDKEuMydGesLxNFzu_EMcTdjrl05DHveii3TuXZCup2woIjLtkN5a6iAmXTkxZhHJ3jaN9gty4Nvr05azonQdItLx1cgrkZSp4cGb-c5I_j6NbOuYt_2h77Bw9hqtuwT7a5OvespF76udftRzv-UdPYD2ooWTk6eYprJj6GTw8D4725_Dr8xJlCFIhaZuIk0NjZz7MiOy6GgPzd5eVnoXsrR9kVpPC9UNA4YQgB46SrsnYl2xdfCQjMu77hEX7eG5q4uIXWzicgrTOo6ioFg25kYD8AiZHxdXBcRT6NUSKpcMGtzvHzUUVRqphxgyvWFZxq5JUamGtoamteGKHsVHI6kpXQrlaOLmLIjPMpCx9Cav1vDabQBTTucxjrVFDZELGUllKNTO5VllcJXIAcbdtpQrFzF1PjW-lM2oQuaVHbonILR1ySzqA9z3Id1_J43-DtzpaKANTL0rXIgStsyRlA3jbv0Z2dD6WqjbzpR_jyqjFYgAbnob6r6HymjHuoD909HBj8ruW8upeo1_DI-obdiBdbcFqc700b1BtauQ2PMim2XZgFrzvFxfjS3x6eHKG1wkd_QYBJRD5 |
linkProvider | Springer Nature |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1ba9RAFD7UCtoX8d61VUdQ8MLQZDIz2Qgitd2ytd1StIV9SzM3WJBs7e5S-uz_8Td6Tm5Win3rc2YmQ8495_IBvE5c8JHBIEdro7hMdeBZEH2ext5nGE8EVbWLjQ708Fh-HavxEvxue2GorLLViZWidlNL_8g3CJ8BXeM4kZ9Pf3JCjaLsaguhUbPFnr84x5Bt9ml3G-n7RoidwdHWkDeoAtzKpD_HS2V4BTS0xvZT6VUh00IFGyfG6RC8SEKh4tCPvEWGtK7Qlia2ZFTr5KVPZILn3oLbklKMKD_puAvwYpQWVWVXNSoRoVWTRRVSUaueTKjeg5qhheTiXzt4xbm9kpit7N3OfbjXOKpss-asB7Dky4dwZ9Sk4h_Br-8L1DLIp6yCGWfbPkzqQiT2lqYQTN99K9yk6e-6YJOSDQgxAdUXbtkiXjtjh_VQ19lHtskOOyQx_gUtq2NU4VjtwyNYlV7ig2I2Z5dalB_D8Y18-yewXE5LvwrMSpeZLHIOfUipTWRsEMJJnzmbRkVsehC13ze3zbhzQt34kVPYgyTJa5LkSJKcSJKLHrzvtpzWsz6uW7zeEi1vxH6W_2XSHrzqHqPAUhamKP10Ua-hQWuR7sHTmtjd29C9TaWi3R9a6l86_H9XeXb9VV7C3eHRaD_f3z3YW4MVUeN5ICuuw_L8bOGfo1c1Ny8qVmZwctOy8wdczzDm |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1ba9RAFD7UFoov4t3VqiMoeCE0mcxMNkKRtrtLa-2yVAt9myZzgQXJ1u4u0mf_nb_Kc5JJrBT71ufMTIace87lA3idWu_iEoMcpUoZiUz5KPe8H2WJcznGE17W7WKHY7V3LD6fyJMV-N32wlBZZasTa0VtZ4b-kW8SPgO6xkkqNn0oi5gMRp_OfkSEIEWZ1hZOowgwC3arHjcWmjwO3MVPDOfmW_sDpP0bzkfDb7t7UUAciIxI-wu8cI7XQyNcmn4mnCxEVkhvkrS0ynvHU1_IxPdjZ5BZjS2UoWkuOdVBOeFSkeK5t2AtQ6uPgeDaznA8OepyGihLss69KlQxXMmQY-VCUiOfSKkahFqluYj4v1byiut7JW1bW8PRXbgT3Fi23fDdPVhx1X1YPwyJ-gfw6-sSdRByMatByNnA-WlTpsTe0oyC2bujwk5D99cFm1ZsSHgKqNxwyy5x4jmbNCNf5x_ZNpt0OGPRDtpdy6j-sd6HR7A6-RQNi_mCXWpgfgjHN_L1H8FqNavcE2BG2LzMY2vRwxSqjEvjObfC5dZkcZGUPYjb76tNGIZOmBzfNQVFSBLdkEQjSTSRRPMevO-2nDWTQK5bvNESTQelMNd_WbgHr7rHKM6UoykqN1s2a2gMW6x68Lghdvc2dH4zIWn3h5b6lw7_31WeXn-Vl7COcqS_7I8PnsFt3oB9ICduwOrifOmeo8u1KF8EXmZwetPi8wfnPzvB |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Survival+after+definitive+%28chemo%29radiotherapy+in+esophageal+cancer+patients%3A+a+population-based+study+in+the+north-East+Netherlands&rft.jtitle=Annals+of+surgical+oncology&rft.au=Smit%2C+Justin+K&rft.au=Muijs%2C+Christina+T&rft.au=Burgerhof%2C+Johannes+G+M&rft.au=Paardekooper%2C+Gabriel&rft.date=2013-06-01&rft.issn=1534-4681&rft.eissn=1534-4681&rft.volume=20&rft.issue=6&rft.spage=1985&rft_id=info:doi/10.1245%2Fs10434-012-2824-2&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1068-9265&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1068-9265&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1068-9265&client=summon |